The medical community is currently locked in a heated battle over whether new Alzheimer’s treatments actually do enough to justify their cost and risks. You’ve probably seen the headlines about Leqembi (lecanemab) or Kisunla (donanemab). They’re hailed as breakthroughs because they finally target the underlying biology of the disease rather than just masking symptoms. But if you talk to neurologists behind closed doors, the excitement is often tempered by a heavy dose of skepticism. We aren't looking at a cure. We’re looking at a modest slowing of decline that many patients might not even notice in their daily lives.
The core of the issue rests on a single question. Is a 27% or 35% slowing of cognitive decline worth the potential for brain swelling and bleeding? For some families, every extra month of "connectedness" is priceless. For others, the trade-offs are terrifying.
The Amyloid Hypothesis Under Fire
For decades, the dominant theory in Alzheimer's research has been the amyloid hypothesis. The idea is simple. Beta-amyloid plaques build up in the brain, gunking up the works and killing neurons. If you clear the gunk, you stop the disease. These new drugs do exactly that—they’re exceptionally good at clearing amyloid.
The problem is that clearing the plaque doesn't magically fix the damage already done. It’s like putting out a fire after the house has already burned halfway down. You stopped the cause, but the structure is still ruined. Recent clinical trials for Eisai and Biogen’s Leqembi showed a 27% slowing of decline over 18 months. Eli Lilly’s Kisunla showed about a 35% slowing.
[Image of amyloid plaques and neurofibrillary tangles in the brain]
What does that look like in real life? On a standard 18-point cognitive scale, it often translates to a difference of less than half a point. Most clinicians agree that a change needs to be at least one full point for a caregiver to actually see a difference in how their loved one functions. We’re splitting hairs with statistics while families are looking for miracles.
Understanding ARIA and the Real Risks
Safety is where the debate gets truly messy. These drugs come with a side effect known as ARIA, or amyloid-related imaging abnormalities. It's a fancy way of saying your brain might swell or bleed.
- ARIA-E: Swelling (edema) in the brain.
- ARIA-H: Small hemorrhages or bleeding.
In the clinical trials for donanemab, nearly a quarter of participants experienced some form of ARIA. Most cases are asymptomatic and show up only on an MRI, but some are severe. A few participants even died. This isn't a "take two pills and call me in the morning" situation. Patients need regular, expensive MRI scans to make sure their brains aren't reacting poorly to the infusion.
It's a high-stakes gamble. You’re asking a patient with early-stage cognitive impairment to risk a stroke or brain swelling for a possibility—not a guarantee—of staying "the same" for a few months longer. For people with the APOE4 gene, which is a major risk factor for Alzheimer’s, the risk of ARIA is even higher. If you have two copies of that gene, some doctors argue you shouldn't touch these drugs at all.
The Massive Price Tag for Modest Gains
We can't ignore the economics. Leqembi costs about $26,500 a year. Kisunla is priced around $32,000 for a year’s worth of treatment. That’s just the drug. It doesn’t include the cost of the infusion center, the specialized nursing staff, or the repeated MRIs needed to monitor for brain bleeds.
Medicare has agreed to cover these drugs, but with strict requirements. This puts a massive strain on the healthcare system. Some analysts worry that the sheer volume of Alzheimer’s patients could bankrupt certain programs if everyone starts these treatments. Is this the best use of our limited healthcare dollars? Or should we be spending that money on better caregiving support and earlier diagnostics?
The debate isn't just about whether the drugs work. It's about value. When a drug costs tens of thousands of dollars and offers a benefit that might be invisible to the naked eye, the pushback from insurance companies and health systems is inevitable.
Who Actually Benefits from These Drugs
It’s not all doom and gloom. For a very specific subset of people, these drugs represent the first real hope in a generation. The key is "early." These treatments are only for people with Mild Cognitive Impairment (MCI) or very early-stage dementia. If your loved one is already in the moderate or severe stages, these drugs won't help. The amyloid damage is too widespread.
The goal is to keep someone in the "mild" stage for as long as possible. If you can delay the move to a nursing home by six months or a year, that’s huge. It's the difference between attending a grandchild's wedding or not. It's the difference between recognizing your spouse or losing that connection.
Identifying the Right Candidate
- Confirmed Amyloid: You can't just have memory loss. You need a PET scan or a spinal tap to prove amyloid is actually there.
- Early Stage: Symptoms must be mild.
- Low Risk: No history of major strokes or blood thinners that increase bleeding risks.
The Logistics Nightmare of Infusion Therapy
The practical reality of getting these drugs is a hurdle most people don't think about. You don't just pick this up at Walgreens. It requires an IV infusion every two to four weeks.
For an 80-year-old living in a rural area, traveling to a specialized infusion center twice a month is a massive burden. It requires a dedicated caregiver to drive them, wait for the infusion, and monitor them for reactions. It's an exhausting cycle. Many patients drop out because the logistics are simply too much to handle.
Shifting Focus to Tau and Beyond
While the world argues about amyloid, researchers are already moving on. Amyloid is likely just the trigger. The real "executioner" of brain cells is a protein called tau. Tau forms tangles inside the neurons, and the amount of tau in the brain correlates much more closely with actual cognitive decline than amyloid does.
The next generation of drugs is targeting tau. The hope is that by combining amyloid-clearing drugs with tau-blocking drugs, we might actually see a significant clinical impact. Think of it like a cocktail for HIV or cancer. We rarely treat complex diseases with just one drug. Alzheimer's won't be any different.
What You Should Do Now
If you or a loved one is facing an Alzheimer’s diagnosis, don't rush into a decision based on a news clip. The debate over effectiveness is real because the benefits are thin and the risks are significant.
Start by getting a definitive diagnosis. Memory loss can be caused by many things—vitamin deficiencies, thyroid issues, or even depression. If it is Alzheimer's, get a genetic test for the APOE4 gene to understand your risk for brain swelling.
Ask your neurologist for the "absolute" benefit, not the "relative" benefit. A "30% slowing" sounds amazing, but if it only means a 0.5-point difference on a scale of 18, you need to decide if that's worth the $30,000 and the risk of a brain bleed.
Demand a clear monitoring plan. You need an MRI schedule before you start. If your doctor isn't talking about ARIA, find a different doctor. This is a complex medical journey, and you need someone who is honest about the limitations of today's science.
The era of amyloid drugs is just the beginning. It's a messy, expensive, and controversial start, but it's finally a move toward treating the cause rather than just the symptoms. Just make sure you know exactly what you're signing up for before you start the infusions.
